Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Mosenzon, O; Blicher, Thalia Marie; Rosenlund, Signe; Eriksson, J.; Heller, S; Hels, Ole Holm; Pratley, R; Sathyapalan, T; Desouza, C.; Abramof, R.; Alpenidze, D.; Aronoff, S.; Astamirova, K.; Barker, B.; Bedel, G.; Belousova, L.; Benson, M.; Beshay, I.; Biggs, W.; Blaze, K.; Bogdanski, P.; Busch, R.; Chaidarun, S.; Chandran, S.; Chang, A.; Chilka, S.; Cleland, A.; Connery, L.; Cornett, G.; Delgado, B.; Donner, T.; Eliasson, K.; Folkerth, S.; Forshaw, K.; Frandsen, H. A.; Frolova, E.; Gandy, W.; Gatipon, G.; Golovach, A.; Gonzalez-Orozco, L.; Gumprecht, J.; Haddad, E.; Hansen, T. K.; Hart, T.; Hasan, S.; Hella, B.; Hellgren, M.; Hewitt, M.; Hietaniemi, S.; Hitz, M.; Houser, P.; Huntley, R.; Jackson, R.; Jakobsen, P. E.; Kapoor, A.; Kargina, L.; Kazakova, E.; Khan, K.; Klein, E.; Knoble, H.; Krasnopeeva (Kabachkova), N; Krzeminski, A.; Kunitsyna, M.; Lawhead, J.; Levin, K.; Levin, P.; Lewy-Alterbaum, L.; Lindmark, S.; Lindsay, R.; Luts, A.; Lysenko, T.; Madsbad, S.; Maxwell, T.; Mbogua, C.; Mcknight, J.; Metsärinne, K.; Milovanova, T.; Morawski, E.; Nabriski, D.; Nguyen, H.; Nicol, P.; Nieminen, S.; Nikkola, A.; Norwood, P.; O'Donnell, P.; Odugbesan, A.; Parker, J.; Pergaeva, Y.; Peskov, A.; Plevin, S.; Pouzar, J.; Reed, J.; Rossing, P.; Sergeeva-Kondrachenko, M.; Shaikh, Z; Shamkhalova, M; Shehadeh, N; Shlesinger, Y; Silver, R; Snyder, B; Soufer, J; Strand, J; Sulosaari, S; Tirosh, A; Traylor, H; Uhlenius, N; Vagapova, G; Yanovskaya, M; Zarutskaya, L; Zhdanova, E

doi:10.1016/S2213-8587(19)30192-5

All Outputs (3)

Physiologically relevant screening of polyphenol-rich commercial preparations for bioactivity in vascular endothelial cells and application to healthy volunteers: a viable workflow and a cautionary tale (2019)
Journal Article
Jones, H., Papageorgiou, M., Gordon, A., Ehtesham, Javed, Z., Wells, L. K., …Sathyapalan, T. (2020). Physiologically relevant screening of polyphenol-rich commercial preparations for bioactivity in vascular endothelial cells and application to healthy volunteers: a viable workflow and a cautionary tale. Biochemical Pharmacology, 173, Article 113754. https://doi.org/10.1016/j.bcp.2019.113754

© 2019 Elsevier Inc. This study describes the screening of 13 commercially-available plant extracts for pharmacological activity modulating vascular function using an endothelial cell model. A French maritime pine bark extract (FMPBE) was found to ha... Read More about Physiologically relevant screening of polyphenol-rich commercial preparations for bioactivity in vascular endothelial cells and application to healthy volunteers: a viable workflow and a cautionary tale.

The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects (2019)
Journal Article
Al-Qaissi, A., Alqarni, S., Javed, Z., Atkin, S. L., Sathyapalan, T., Vince, R., & Madden, L. A. (2019). The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects. Endocrine, https://doi.org/10.1007/s12020-019-02059-9

© 2019, The Author(s). Background: A retrospective analysis was carried out from patients and controls during the past 5 years from a series of studies investigating endothelial microparticles (MP). Methods: In total, 319 samples from 207 individuals... Read More about The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects.

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial (2019)
Journal Article
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J., Heller, S., Hels, O. H., …Zhdanova, E. (2019). Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes and Endocrinology, 7(7), 515-527. https://doi.org/10.1016/S2213-8587%2819%2930192-5

Background: Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly associated with renal impairment, restricting treatment options. We ai... Read More about Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.